Nirmatrelvir CAS 2628280-40-8 Potent SARS-CoV-2 3CL Protease Inhibitor for COVID-19 Antiviral Research hfd
TDS
2628280-40-8
Reagent Grade
99%
qingdao
//
5g, 25g, 100g, 500g
2026-09-30
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferencePF-07321332 is an azabicyclohexane that is (1R,5S)-3-azabicyclo[3.1.0]hexane substituted by {(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}aminoacyl, 3-methyl-N-(trifluoroacetyl)-L-valinamide, methyl and methyl groups at positions 2S, 3, 6 and 6, respectively. It is an inhibitor of SARS-CoV-2 main protease which is currently under clinical development for the treatment of COVID-19. It has a role as an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor and an anticoronaviral agent. It is a nitrile, a member of pyrrolidin-2-ones, a secondary carboxamide, a pyrrolidinecarboxamide, a tertiary carboxamide, an organofluorine compound and an azabicyclohexane.
PF-07321332 is an oral COVID-19 antiviral clinical candidate. By inhibiting the main protease, PF-07321332 prevents the virus from cleaving long protein chains into the parts it needs to reproduce itself.
Paxlovid is a new potential drug discovered by Pfizer. Paxlovid is composed of two active ingredients, Nirmatrelvir and Ritonavir. Similarly, a mixture of Lopinavir and Ritonavir drugs is already used against HIV. Ritonavir is a drug approved in 1996 which is widely used, not exclusively, to treat HIV/AIDS. Another component of Paxlovid, Nirmatrelvir (PF-07321332) is a new potential drug developed by Pfizer. It inhibits the SARS-CoV-1 virus protease (Mpro), which fragments long protein chains into the parts the virus needs to reproduce. Nirmatrelvir acts as a substrate for the virus protease in the cell, thereby deceiving the virus and blocking its replication.Certificates-
TDS
Basic Info-
Product Name:
Paxlovid
Other Name:PF-07321332;3-Azabicyclo[3.1.0]hexane-2-carboxamide,N- [(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]- 3-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2- trifluoroacetyl)amino]butyl]-6,6-dimethyl-, (1R,2S,5S)-;PF07321332(Paxlovid);nirmatrelvir;Nirmatrelvir (PF-07321332);PF-07321332-005;(1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;3-Azabicyclo[3.1.0]hexane-2-carboxamide,N- [(1S)-1-cyano-2-[...
CAS No.:2628280-40-8
Molecular Formula:C23H32F3N5O4
InChIKeys:LIENCHBZNNMNKG-OJFNHCPVSA-N
Molecular Weight:499.53
Exact Mass:499.24063901
EC Number:605-001-5
UNII:7R9A5P7H32
Color/Form:White to off-white
Categories:
Characteristics-
Density:
1.267±0.06 g/cm3(Predicted)
Boiling Point:742.4±60.0 °C(Predicted)
PKA:10.26±0.46(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Location:
RONGSHENG BEIYUANDAJIE 9, LICHENG DISTRICT,JINAN, SHANDONG CHINA
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product